Full Press Release Details
TELA Bio Appoints Jeffrey Blizard as President
Company Further Strengthens Executive Leadership
Team to Drive Next Phase of Growth
MALVERN, PA - June 2, 2025 -
TELA Bio, Inc. ("TELA Bio") a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction
solutions, today announced the appointment of Jeffrey Blizard as President of TELA Bio, effective immediately. Mr. Blizard, who has
served on TELA Bio's Board of Directors for the past year, brings deep industry experience and proven leadership to this expanded
"This is an important inflection point
for TELA Bio," said Antony Koblish, Co-Founder and Chief Executive Officer of TELA Bio. "As we move into the next phase of
our growth trajectory, we believe the addition of Jeff-a highly respected leader with a track record of scaling businesses and inspiring
teams-will amplify our ability to compete and win in a dynamic market. We are confident that this leadership evolution will drive
meaningful commercial performance and reinforce our commitment to delivering exceptional value to our customers, partners, and shareholders."
Mr. Blizard joins TELA Bio from Abiomed,
a Johnson & Johnson company, where he served as Global Head of Surgical Sales. Under his leadership, the Surgical Division of
Abiomed grew substantially over multiple years. In addition, he brings extensive commercial experience from leading medtech companies
including Medtronic, Intuitive Surgical, and Boston Scientific.
"TELA Bio has built an extraordinary
foundation and a differentiated portfolio that is redefining soft tissue reconstruction," said Jeffrey Blizard, newly appointed
President of TELA Bio. "I'm thrilled to join a mission-driven team with such momentum and look forward to working alongside
our talented leadership and commercial teams to accelerate execution, deepen customer relationships, and scale our impact."
About TELA Bio, Inc.
TELA Bio, Inc. (NASDAQ: TELA) is a commercial-stage medical technology
company focused on providing innovative technologies that optimize clinical outcomes by prioritizing the preservation and restoration
of the patient's own anatomy. The Company is committed to providing surgeons with advanced, economically effective soft-tissue reconstruction
solutions that leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials.
For more information, visit www.telabio.com.
Caution Regarding Forward-Looking Statements
This press release contains forward-looking statements within the
meaning of The Private Securities Litigation Reform Act of 1995. Words such as "may," "might," "will,"
"should," "believe," "expect," "anticipate," "estimate," "continue," "predict,"
"forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent,
belief, or current expectations are forward-looking statements and reflect the current beliefs of TELA Bio's management. These statements
are not guarantees of future performance and are subject to certain risks, uncertainties and other factors that could cause actual results
and events to differ materially and adversely from those indicated by such forward-looking statements. These risks and uncertainties
are described more fully in the "Risk Factors" section and elsewhere in our filings with the Securities and Exchange Commission
and available at www.sec.gov, including in our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Any
forward-looking statements that we make in this announcement speak only as of the date of this press release, and TELA Bio assumes no
obligation to update forward-looking statements whether as a result of new information, future events or otherwise after the date of
this press release, except as required under applicable law.